{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:26:14Z","timestamp":1792664774643,"version":"4.5.0"},"reference-count":32,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018286","name":"Dutch Arthritis Society","doi-asserted-by":"publisher","award":["15-1-303"],"award-info":[{"award-number":["15-1-303"]}],"id":[{"id":"10.13039\/100018286","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,11,3]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The objectives are to evaluate variation in systemic disease activity (European Alliance of Associations For Rheumatology (EULAR) Sj\u00f6gren\u2019s Syndrome Disease Activity Index (ESSDAI)) over time at group and individual patient level and to assess associations of ESSDAI low disease activity (LDA) with other outcome measures in a standard-of-care cohort of patients with Sj\u00f6gren\u2019s disease (SjD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with SjD participating in a prospective longitudinal study (REgistry of Sj\u00f6gren Syndrome LongiTudinal cohort) fulfilling the 2016 American College of Rheumatology\/EULAR classification criteria with \u22652 years of follow-up were included. ESSDAI was assessed at least yearly, up to 5 years. Patient-reported, objective glandular and laboratory outcomes were compared between patients with ESSDAI LDA (score&lt;5) for &lt;75%\u2009vs \u226575% of time.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 265 included patients with SjD, 236 (89%) were women, median disease duration was 6 years (IQR 2\u201310) and 114 (43%) received immunosuppressive treatment at some point during follow-up. At group level, median ESSDAI decreased slightly, from 4 (IQR 2\u20137) at baseline to 3 (IQR 2\u20135) at year 5, with a concomitant decrease in variation, indicating regression to the mean. At the individual patient level, ESSDAI varied in the majority of patients: 50\/102 (49%) untreated patients with ESSDAI&lt;5 at baseline changed to ESSDAI\u22655 at least once during follow-up. Of the untreated patients with ESSDAI\u22655 at baseline, 41\/45 (91%) changed to ESSDAI&lt;5. Patients with ESSDAI LDA for \u226575% of time showed better outcomes on saliva production.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this cohort of patients with SjD, overall ESSDAI slightly decreased during 5 years of follow-up, whereas at individual patient level, large variation was seen over time for the majority of patients. Longer time in ESSDAI LDA was associated with better salivary gland outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2024-004753","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T22:35:11Z","timestamp":1737585311000},"page":"e004753","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Systemic disease activity measured with ESSDAI varies largely over 5 years in a prospective, longitudinal cohort of patients with Sj\u00f6gren\u2019s disease"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-5449","authenticated-orcid":false,"given":"Liseth","family":"de Wolff","sequence":"first","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenny","family":"Verstappen","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alja","family":"Stel","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greetje","family":"van Zuiden","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien","family":"van Nimwegen","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"Vissink","sequence":"additional","affiliation":[{"name":"Oral and Maxillofacial Surgery, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans","family":"Kroese","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4422-7640","authenticated-orcid":false,"given":"Suzanne","family":"Arends","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrika","family":"Bootsma","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"2025090313294471000_11.1.e004753.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1702514"},{"key":"2025090313294471000_11.1.e004753.2","first-page":"32","article-title":"Primary Sj\u00f6gren\u2019s syndrome","volume":"27","author":"Bowman","year":"2018","journal-title":"Lupus (Los Angel)"},{"key":"2025090313294471000_11.1.e004753.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216114"},{"key":"2025090313294471000_11.1.e004753.4","first-page":"2225","article-title":"Selection of study endpoints and patients for clinical trials in primary Sj\u00f6gren\u2019s syndrome","volume":"40","author":"Arends","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313294471000_11.1.e004753.5","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary Sj\u00f6gren\u2019s syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"van Nimwegen","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025090313294471000_11.1.e004753.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218599"},{"key":"2025090313294471000_11.1.e004753.7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"2025090313294471000_11.1.e004753.8","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sj\u00f6gren\u2019s Syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090313294471000_11.1.e004753.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218467"},{"key":"2025090313294471000_11.1.e004753.10","first-page":"283","article-title":"Ten years of the ESSDAI: is it fit for purpose?","volume":"38 Suppl 126","author":"de Wolff","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313294471000_11.1.e004753.11","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyh299"},{"key":"2025090313294471000_11.1.e004753.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206008"},{"key":"2025090313294471000_11.1.e004753.13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"The Lancet"},{"key":"2025090313294471000_11.1.e004753.14","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41591-024-03009-3","article-title":"CD40 ligand antagonist dazodalibep in Sj\u00f6gren\u2019s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial","volume":"30","author":"St. Clair","year":"2024","journal-title":"Nat Med"},{"key":"2025090313294471000_11.1.e004753.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224691"},{"key":"2025090313294471000_11.1.e004753.16","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(24)01211-X","article-title":"Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sj\u00f6gren\u2019s disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study","volume":"404","author":"Fisher","year":"2024","journal-title":"The Lancet"},{"key":"2025090313294471000_11.1.e004753.17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200482"},{"key":"2025090313294471000_11.1.e004753.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210571"},{"key":"2025090313294471000_11.1.e004753.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.110619"},{"key":"2025090313294471000_11.1.e004753.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143743"},{"key":"2025090313294471000_11.1.e004753.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2007.02.003"},{"key":"2025090313294471000_11.1.e004753.22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4078\/jrd.2019.26.3.191","article-title":"Longitudinal Changes in the European League Against Rheumatism Sj\u00f6gren\u2019s Syndrome Patient Reported Index in Real-Life Practice","volume":"26","author":"Kim","year":"2019","journal-title":"J Rheum Dis"},{"key":"2025090313294471000_11.1.e004753.23","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1093\/rheumatology\/keaa687","article-title":"Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sj\u00f6gren\u2019s syndrome","volume":"60","author":"Park","year":"2021","journal-title":"Rheumatol Sunnyvale"},{"key":"2025090313294471000_11.1.e004753.24","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/rheumatology\/key392","article-title":"Is early-onset primary Sj\u00f6gren\u2019s syndrome a worse prognosis form of the disease?","volume":"58","author":"Anquetil","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313294471000_11.1.e004753.25","doi-asserted-by":"crossref","unstructured":"Ramos-Casals M , Brito-Zer\u00f3n P , Solans R , et al . Systemic involvement in primary Sj\u00f6gren\u2019s syndrome evaluated by the EULAR-SS disease activity index. 2014;53:321\u201331. doi:10.1093\/rheumatology\/ket349","DOI":"10.1093\/rheumatology\/ket349"},{"key":"2025090313294471000_11.1.e004753.26","first-page":"121","article-title":"Severe, life-threatening phenotype of primary Sj\u00f6gren\u2019s syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry)","volume":"36 Suppl 112","author":"Flores-Ch\u00e1vez","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313294471000_11.1.e004753.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206418"},{"key":"2025090313294471000_11.1.e004753.28","article-title":"Mortality risk factors in primary Sj\u00f6gren syndrome: a real-world, retrospective, cohort study","volume":"61","author":"Brito-Zer\u00f3n","year":"2023","journal-title":"EClinMed"},{"key":"2025090313294471000_11.1.e004753.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204615"},{"key":"2025090313294471000_11.1.e004753.30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200460"},{"key":"2025090313294471000_11.1.e004753.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-222054"},{"key":"2025090313294471000_11.1.e004753.32","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","article-title":"Composite of Relevant Endpoints for Sj\u00f6gren\u2019s Syndrome (CRESS): development and validation of a novel outcome measure","volume":"3","author":"Arends","year":"2021","journal-title":"Lancet Rheumatol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-004753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:29:58Z","timestamp":1756931398000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-004753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,22]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/rmdopen-2024-004753"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-004753","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}